Zacks Company Profile for Eiger BioPharmaceuticals, Inc. (EIGRQ : OTC) |
|
|
|
Company Description |
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.
Number of Employees: 25 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $ |
Daily Weekly Monthly
 |
20 Day Moving Average: shares |
Shares Outstanding: 1.48 (millions) |
Market Capitalization: $ (millions) |
Beta: |
52 Week High: $15.00 |
52 Week Low: $1.10 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
% |
% |
12 Week |
% |
% |
Year To Date |
% |
% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
David Apelian - Chief Executive Officer and Director
Thomas J. Dietz - Chairman
William G. Kachioff - Chief Financial Officer
Evan Loh - Director
Amit K. Sachdev - Director
|
|
Peer Information
Eiger BioPharmaceuticals, Inc. (CORR.)
Eiger BioPharmaceuticals, Inc. (RSPI)
Eiger BioPharmaceuticals, Inc. (CGXP)
Eiger BioPharmaceuticals, Inc. (BGEN)
Eiger BioPharmaceuticals, Inc. (GTBP)
Eiger BioPharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28249U204
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
|
|
Share - Related Items
Shares Outstanding: 1.48
Most Recent Split Date: 1.00 (0.03:1)
Beta:
Market Capitalization: $ (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: % |
Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: - |
|
|
|
|